204 related articles for article (PubMed ID: 35968927)
21. Engineered exosome-like nanovesicles suppress tumor growth by reprogramming tumor microenvironment and promoting tumor ferroptosis.
Hu S; Ma J; Su C; Chen Y; Shu Y; Qi Z; Zhang B; Shi G; Zhang Y; Zhang Y; Huang A; Kuang Y; Cheng P
Acta Biomater; 2021 Nov; 135():567-581. PubMed ID: 34506976
[TBL] [Abstract][Full Text] [Related]
22. Improving Breast Cancer Responses to Immunotherapy-a Search for the Achilles Heel of the Tumor Microenvironment.
Jenkins S; Wesolowski R; Gatti-Mays ME
Curr Oncol Rep; 2021 Mar; 23(5):55. PubMed ID: 33755828
[TBL] [Abstract][Full Text] [Related]
23. Nanodrug regulates lactic acid metabolism to reprogram the immunosuppressive tumor microenvironment for enhanced cancer immunotherapy.
Tian LR; Lin MZ; Zhong HH; Cai YJ; Li B; Xiao ZC; Shuai XT
Biomater Sci; 2022 Jul; 10(14):3892-3900. PubMed ID: 35686599
[TBL] [Abstract][Full Text] [Related]
24. l-arginine and docetaxel synergistically enhance anti-tumor immunity by modifying the immune status of tumor-bearing mice.
Cao Y; Wang Q; Du Y; Liu F; Zhang Y; Feng Y; Jin F
Int Immunopharmacol; 2016 Jun; 35():7-14. PubMed ID: 27003114
[TBL] [Abstract][Full Text] [Related]
25. Co-delivery of anionic epitope/CpG vaccine and IDO inhibitor by self-assembled cationic liposomes for combination melanoma immunotherapy.
Su Q; Wang C; Song H; Zhang C; Liu J; Huang P; Zhang Y; Zhang J; Wang W
J Mater Chem B; 2021 May; 9(18):3892-3899. PubMed ID: 33928989
[TBL] [Abstract][Full Text] [Related]
26. Salicylic acid-based hypoxia-responsive chemodynamic nanomedicines boost antitumor immunotherapy by modulating immunosuppressive tumor microenvironment.
Sun K; Yu J; Hu J; Chen J; Song J; Chen Z; Cai Z; Lu Z; Zhang L; Wang Z
Acta Biomater; 2022 Aug; 148():230-243. PubMed ID: 35724919
[TBL] [Abstract][Full Text] [Related]
27. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity.
Chen SH; Dominik PK; Stanfield J; Ding S; Yang W; Kurd N; Llewellyn R; Heyen J; Wang C; Melton Z; Van Blarcom T; Lindquist KC; Chaparro-Riggers J; Salek-Ardakani S
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599020
[TBL] [Abstract][Full Text] [Related]
28. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
[TBL] [Abstract][Full Text] [Related]
29. Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1.
D'Alterio C; Buoncervello M; Ieranò C; Napolitano M; Portella L; Rea G; Barbieri A; Luciano A; Scognamiglio G; Tatangelo F; Anniciello AM; Monaco M; Cavalcanti E; Maiolino P; Romagnoli G; Arra C; Botti G; Gabriele L; Scala S
J Exp Clin Cancer Res; 2019 Oct; 38(1):432. PubMed ID: 31661001
[TBL] [Abstract][Full Text] [Related]
30. DTX@VTX NPs synergy PD-L1 immune checkpoint nanoinhibitor to reshape immunosuppressive tumor microenvironment for enhancing chemo-immunotherapy.
Zhang R; Wan Y; Lv H; Li F; Lee CS
J Mater Chem B; 2021 Sep; 9(36):7544-7556. PubMed ID: 34551052
[TBL] [Abstract][Full Text] [Related]
31. Ultra-thin layered double hydroxide-mediated photothermal therapy combine with asynchronous blockade of PD-L1 and NR2F6 inhibit hepatocellular carcinoma.
Lu YF; Zhou JP; Zhou QM; Yang XY; Wang XJ; Yu JN; Zhang JG; Du YZ; Yu RS
J Nanobiotechnology; 2022 Jul; 20(1):351. PubMed ID: 35907841
[TBL] [Abstract][Full Text] [Related]
32. Immunosuppressive circuits in tumor microenvironment and their influence on cancer treatment efficacy.
Tuccitto A; Shahaj E; Vergani E; Ferro S; Huber V; Rodolfo M; Castelli C; Rivoltini L; Vallacchi V
Virchows Arch; 2019 Apr; 474(4):407-420. PubMed ID: 30374798
[TBL] [Abstract][Full Text] [Related]
33. Dynamic tagging to drive arginine nano-assembly to metabolically potentiate immune checkpoint blockade therapy.
Zang J; Yang Y; Zheng X; Yang Y; Zhao Y; Miao Z; Zhang T; Gu J; Liu Y; Yin W; Ma X; Ding Q; Dong H; Li Y; Li Y
Biomaterials; 2023 Jan; 292():121938. PubMed ID: 36493715
[TBL] [Abstract][Full Text] [Related]
34. A Hierarchical Structured Fiber Device Remodeling the Acidic Tumor Microenvironment for Enhanced Cancer Immunotherapy.
Li Y; Yuan R; Luo Y; Guo X; Yang G; Li X; Zhou S
Adv Mater; 2023 May; 35(21):e2300216. PubMed ID: 36912443
[TBL] [Abstract][Full Text] [Related]
35. Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy.
Liu X; Si F; Bagley D; Ma F; Zhang Y; Tao Y; Shaw E; Peng G
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36192086
[TBL] [Abstract][Full Text] [Related]
36. Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy.
Ma Z; Zhang W; Dong B; Xin Z; Ji Y; Su R; Shen K; Pan J; Wang Q; Xue W
Theranostics; 2022; 12(11):4965-4979. PubMed ID: 35836810
[No Abstract] [Full Text] [Related]
37. Targeting Inhibition of Accumulation and Function of Myeloid-Derived Suppressor Cells by Artemisinin via PI3K/AKT, mTOR, and MAPK Pathways Enhances Anti-PD-L1 Immunotherapy in Melanoma and Liver Tumors.
Zhang M; Wang L; Liu W; Wang T; De Sanctis F; Zhu L; Zhang G; Cheng J; Cao Q; Zhou J; Tagliabue A; Bronte V; Yan D; Wan X; Yu G
J Immunol Res; 2022; 2022():2253436. PubMed ID: 35785030
[TBL] [Abstract][Full Text] [Related]
38. Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME).
Bretz AC; Parnitzke U; Kronthaler K; Dreker T; Bartz R; Hermann F; Ammendola A; Wulff T; Hamm S
J Immunother Cancer; 2019 Nov; 7(1):294. PubMed ID: 31703604
[TBL] [Abstract][Full Text] [Related]
39. Regulating the Obesity-Related Tumor Microenvironment to Improve Cancer Immunotherapy.
Fang H; Wu Y; Chen L; Cao Z; Deng Z; Zhao R; Zhang L; Yang Y; Liu Z; Chen Q
ACS Nano; 2023 Mar; 17(5):4748-4763. PubMed ID: 36809912
[TBL] [Abstract][Full Text] [Related]
40. Strengthening the Combinational Immunotherapy from Modulating the Tumor Inflammatory Environment via Hypoxia-Responsive Nanogels.
Luo W; Zeng Y; Song Q; Wang Y; Yuan F; Li Q; Liu Y; Li S; Jannatun N; Zhang G; Li Y
Adv Healthc Mater; 2024 Mar; 13(8):e2302865. PubMed ID: 38062634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
